UBS AM
NAGE

UBS AM’s Niagen Bioscience NAGE Stock Holding History

UBS AM’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$842 Hold
264
– – ﹤0.01% 3628
2026
Q1 		$1.16K Sell
264
-50,889
-99% -$275K ﹤0.01% 3664
2025
Q4 		$325K Buy
51,153
+21,871
+75% +$152K ﹤0.01% 2401
2025
Q3 		$273K Buy
29,282
+140
+0.5% +$1.41K ﹤0.01% 2209
2025
Q2 		$420K Buy
+29,142
New +$288K ﹤0.01% 2504

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS AM's NAGE Position: Q2 2026 in Review

UBS AM held its Niagen Bioscience (NAGE) position steady in Q2 2026 at 264 shares worth $842. The position accounts for ﹤0.01% of the portfolio, ranked #3628.

UBS AM first reported a position in NAGE in Q2 2025 and has held it in 5 quarters since. The position peaked at $420K in Q2 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • UBS AM held 264 shares of Niagen Bioscience worth $842 as of Q2 2026.
  • UBS AM left its Niagen Bioscience share count unchanged in Q2 2026.
  • Niagen Bioscience made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3628 holding.
  • UBS AM first reported a position in Niagen Bioscience in Q2 2025 and has held it in 5 quarters since.
  • UBS AM's Niagen Bioscience position peaked at $420K in Q2 2025.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.